Current Report · Items 8.01, 9.01 · 8-K

Kairos Pharma, Ltd.

KAPANYSE_AMERICANEQUITYCurrent

Other Events

Filed Nov 5, 2026Accepted Nov 5, 2026, 9:15 AM ESTCIK 1962011Accession 0001493152-26-050094

View company →Permanent SEC source ↗

Press release in this filing

Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology →

Company context

Current securities

KAPANYSE_AMERICAN · EQUITY · Current

Recent company filings

Registered securities in this filing

Kairos Pharma, Ltd. · 8-K · Filed 2026-11-05

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.001 per share

Symbol: KAPA
Exchange: NYSEAMER
Classification: COMMON
Status: Current

Filing context

Context: AsOf2026-11-05

Dimensions: Not supplied

Accession 000149315226050094 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events

Item 8.01. Other Events. On November 5, 2026, Kairos Pharma, Ltd. (the “Company”) issued a press release announcing that the Company has been named a winner of the 2026 Biotech Breakthrough Awards in the category of Cancer Immunology Solution of the Year for its work with ENV-105 (carotuximab) targeting cancer drug resistance in metastatic prostate cancer and non-small cell lung cancer. A copy of the press release is furnished herewith as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed “filed” for any purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such Section. The information in this Current Report on Form 8-K shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Filed exhibits (1)

EX-99.1 (by filename) ex99-1.htm

Exhibit 99.1 Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology Company’s lead candidate ENV-105 has been selected as winner of the Cancer Immunology Solution of the Year Award LOS ANGELES - November 5, 2026 - Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company targeting drug resistance in cancer, announces that it has been named a winner of the 2026 Biotech Breakthrough Awards in the category of Cancer Immunology Solution of the Year for its work with ENV-105 targeting cancer drug resistance in metastatic prostate cancer and non-small cell lung cancer. Kairos Pharma was recognized for its differentiated approach to targeting the biological mechanisms that allow tumors to evade treatment. Rather than developing standalone therapies, Kairos is advancing resistance-modulating treatments designed to restore and extend the effectiveness of existing cancer therapies. At the center of this strategy is ENV-105 (carotuximab), an investigational neutralizing antibody designed to inhibit pathways involved in cancer stem cells and therapy resistance. ENV-105 is being developed in combination with standard-of-care therapies with the goal o…

Open exhibit ↗

Get the free weekly BCS email.